Initial Treatment Approach for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

First-Line Treatment Considerations

The treatment selection should be based on severity of symptoms, comorbidities, patient preferences, and access to treatment, as suggested by the Annals of Oncology 1
Patient preferences and access to treatment are important factors in selecting the initial therapy, according to Praxis Medical Insights: Practical Summaries of Clinical Guidelines 2

For neuropathic pain associated with CIDP, duloxetine is recommended as first-line therapy with strong evidence showing moderate clinical benefit, as reported by Praxis Medical Insights: Practical Summaries of Clinical Guidelines 2
Pregabalin or gabapentin can be considered as second-line options for neuropathic pain if duloxetine is ineffective or contraindicated, with evidence supported by Annals of Oncology 1 and Praxis Medical Insights: Practical Summaries of Clinical Guidelines 2